News
Groundbreaking: NO MORE LIMITATIONS FOR CORD BLOOD USE
There is no translation available.On 17 April 2023, the FDA gave approval to the Gamida Cell product “Omisirge” (known also as omidubicel or NiCord)1. This is the first FDA market approval of an “expanded” cord blood product, which means that the number of stem cells in cord blood is no longer it’s...
MoreAutologus cord blood in autism treatment- new clinical trial in Romania
There is no translation available.Autologus cord blood in autism treatment- new clinical trial in Romania Researchers at Bioforum Foundation have been studying whether intravenous infusions of cord blood stem cells can help young children with autism spectrum disorder (ASD). The leader of this rese...
MoreMultiplication of umbilical cord blood stem cells as a chance for cancer patients
There is no translation available. Multiplication of umbilical cord blood stem cells as anew hope for cancer patients Cord blood stem cells are used in medicine for treatment of over 80 different diseases such as leukemias, lymphomas and sickle cell anemia for over 30 years. It has also been prove...
MoreThe FamiCord Group strengthens its position in Turkey
There is no translation available.The FamiCord Group strengthens its position in Turkey by investing in astem cell bank belonging to the Acıbadem Healthcare Group FamiCord Group has concluded an investment agreement regarding the purchase of shares in the Turkish stem cell bank which has operated s...
More